Long-lasting poliovirus-neutralizing antibodies among Argentinean population immunized with four or five oral polio vaccine doses 1 month to 19 years previously

Viral Immunology

Volumn 20, Issue 1, 2007, Pages 3-10

  Nates, Silvia V ^a   Martinez, Laura C ^a   Barril, Patricia A ^a,b   Ferreyra, Leonardo J ^a   Giordano, Miguel O ^a   Masachessi, Gisela ^a,b   Isa, Maria Beatriz ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARGENTINA; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMORAL IMMUNE DEFICIENCY; INFANT; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; REVACCINATION; SEROPREVALENCE; SEROTYPE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HUMANS; INFANT; NEUTRALIZATION TESTS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; TIME FACTORS; VACCINATION;

HUMAN POLIOVIRUS 3; POLIOVIRUS;

EID: 34247241146     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.0071     Document Type: Article

References (23)

1. Bass JW, Halstead SB, Fischer GW, Podgore JK, and Wiebe RA: Oral polio vaccine: Effect of booster vaccination one to 14 years after primary series. JAMA 1978;239:2252-2255.
2. Farisano G, Trivello R, Moschen ME, Bonello C, Baldo V, Moretti G, Majori S, Marin F, Piron L, and Renzulli G: Poliovirus neutralizing antibody persistence after vaccination with the Sabin vaccine: A follow-up study. Ann Clin Lab Sci 1995;25:200-206.
3. Grotto I, Handsher R, Gdalevich M, Mimouni D, Huerta M, Green MS, Mendelson E, and Shpilberg O: Decline in immunity to polio among young adults. Vaccine 2001;19:4162-4166.
4. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, Andre J, Blackman E, Freeman CJ, Jorba J, Sutter R, Tambini G, Venczel L, Pedreira C, Laender F, Shimizu H, Yoneyama T, Miyamura T, van der Avoort H, Oberste MS, Kilpatrick D, Cochi S, Pallansch M, and de Cuadros C: Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002;296:356-359.
5. Lapinleimu K, and Stenvik M: Experiences with polio vaccination and herd immunity in Finland. Dev Biol Stand 1981;47:241-246.
6. Mastroeni I, Patti AM, Fabrizi A, Santi AL, Manduca AM, Vescia N, Squarcione S, and Fara GM: Immunity status against poliomyelitis in persons 13-14 years old living in Rome. Vaccine 1997;15:747-750.
7. Ministerio de Salud de la Provincia de Córdoba, Secretaría de Salud de la Municipalidad de Córdoba, Comitato Internazionale per lo Sviluppo dei Popoli. Cooperación Italo-Argentina Programa de Salud Pública en la Ciudad de Córdoba. Vigilancia Epidemiológica de las Enfermedades Transmisibles: Córdoba 1970/1989, 1st ed. Ediciones Cincos, Córdoba, Argentina, 1991.
8. Murph JR, Grose C, McAndrew P, Mickiewicz C, Mento S, Cano F, Ritchey M, and Stout MG: Sabin inactivated trivalent poliovirus vaccine: First clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988;7:760-765.
9. Ogra PL, and Karzon DT: Distribution of poliovirus antibody serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovirus. J Immunol 1969;102:1423-1430.
10. Patriarca PA, Wright PF, and John TJ: Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: Review. Rev Infect Dis 1991;13 926-939.
11. Posey DL, Linkins RW, Oliveria MJ, Monteiro D, and Patriarca PA: J Infect Dis 1997;175:S258-S263.
12. Reali D, Carducci A, and Ruschi MA: Serum antibodies to polioviruses in a Tuscan population, Italy. Eur J Epidemiol 1990;6:309-312.
13. Rousseau WE, Noble GR, Tegtmeier GE, Jordan MC, and Chin TDY: Persistence of poliovirus neutralizing antibodies eight years after immunization with live, attenuated-virus vaccine. N Engl J Med 1973;289:1357-1359.
14. Salk J: Immunization against poliomyelitis: Risk/benefit/cost in a changing context. Dev Biol Stand 1979;43:151-157.
15. Schoub BD, Blackburn NK, and McAnerney JM: Seroprevalence to polio in personnel at a virology institute. J Infect 2001;43:128-131.
16. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, and Hadler SC: Defining surrogate serologic test with respect to predicting protective vaccine efficacy: Poliovirus vaccination. Ann N Y Acad Sci 1995;754:289-299.
17. Sutter RW, Suleiman ATM, Malankar P, Al-Khusaiby S, Mehta F, Clements GB, Pallansch MA, and Robertson SE: Trial of supplemental dose of tour poliovirus vaccines. N Engl J Med 2000;343:767-773.
18. Triassi M, Ribera G, Barruffo L, Barbone S, Medda E, and Grandolfo ME: Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to over 15 years before. Eur J Epidemiol 1996;12:5-8.
19. Trivello R, Farisano G, Bonello C, Moschen ME, Baldo V, Majori S, Moretti G, Marin V, Prion L, and Renzulli G: Immunity status to poliovirus in Veneto region (north-east Italy): A seroepidemiological survey. Ann Clin Lab Sci 1994;24:542-547.
20. Trivello R, Renzulli G, Farisano G, Bonillo C, Moschen ME, Gasparini V, and Benussi G: Persistence of poliovirus-neutralizing antibodies 2-16 years after immunization with live attenuated vaccine: A seroepidemiologic survey in the mainland of Venice. Epidemiol Infect 1988;101:605-609.
21. World Health Organization. 115th Executive board report: Eradication of poliomyelitis. Report by the Secretariat. World Health Organization, Geneva, Switzerland, 2004. http://www.polioeradication.org.
22. World Health Organization. Guidelines for WHO/EPI collaborative studies on poliomyelitis. Standard procedure for determining immunity to poliovirus using the microneutralization test. WHO/EPI/GEN 93.9. World Health Organization, Geneva, Switzerland, 1993.
23. World Health Organization. Immunological basis for immunization. Module 6: Poliomyelitis. WHO/EPI/GEN/93.16. World Health Organization, Geneva, Switzerland, 1993. www.who.int/vaccines-documents/DOCSPDF-IBI-e/mod6_e.pdf